101. Sexually transmitted infections and depot medroxyprogesterone acetate do not impact protection from simian HIV acquisition by long-acting cabotegravir in macaques
- Author
-
Janet M. McNicholl, Walid Heneine, Chunxia Zhao, Lara E. Pereira, Roopa Luthra, Sundaram A. Vishwanathan, George K. Khalil, Chuong Dinh, Michelle J. Gary, J. Gerardo García-Lerma, Monica M. Morris, William Spreen, and James Mitchell
- Subjects
simian HIV ,Vaginal discharge ,macaques ,Pyridones ,Immunology ,Sexually Transmitted Diseases ,Simian Acquired Immunodeficiency Syndrome ,Physiology ,HIV Infections ,Diketopiperazines ,Medroxyprogesterone Acetate ,medicine.disease_cause ,chemistry.chemical_compound ,Cabotegravir ,Basic Science ,medicine ,Animals ,Humans ,Immunology and Allergy ,Medroxyprogesterone acetate ,sexually transmitted infection ,Seroconversion ,Survival analysis ,business.industry ,HIV ,long-acting cabotegravir ,virus diseases ,medicine.disease ,depot medroxyprogesterone acetate ,Infectious Diseases ,chemistry ,Macaca ,Female ,Trichomonas vaginalis ,Syphilis ,medicine.symptom ,Chlamydia trachomatis ,business ,medicine.drug - Abstract
Objective: We had previously shown that long-acting cabotegravir (CAB-LA) injections fully protected macaques from vaginal simian HIV (SHIV) infection. Here, we reassessed CAB-LA efficacy in the presence of depot medroxyprogesterone acetate and multiple sexually transmitted infections (STIs) that are known to increase HIV susceptibility in women. Design: Two macaque models of increasing vaginal STI severity were used for efficacy assessment. Methods: The first study (n = 11) used a double STI model that had repeated exposures to two vaginal STI, Chlamydia trachomatis and Trichomonas vaginalis. Six animals were CAB-LA treated and five were controls. The second study (n = 9) included a triple STI model with repeated exposures to C. trachomatis, T. vaginalis and syphilis, and the contraceptive, depot medroxyprogesterone acetate (DMPA). Six animals were CAB-LA treated and three were controls. All animals received up to 14 vaginal SHIV challenges. A survival analysis was performed to compare the number of SHIV challenges to infection in the drug-treated group compared with untreated controls over time. Results: All six CAB-LA treated animals in both models, the double STI or the triple STI-DMPA model, remained protected after 14 SHIV vaginal challenges, while the untreated animals became SHIV-infected after a median of two challenges (log-rank P
- Published
- 2021
- Full Text
- View/download PDF